Department of Medical Oncology, Complejo Hospitalario de Navarra, IdiSNA Navarra Institute for Health Research, Navarra Public Health System, Pamplona, Navarra, Spain.
Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Crit Rev Oncol Hematol. 2016 May;101:193-206. doi: 10.1016/j.critrevonc.2016.03.013. Epub 2016 Mar 11.
Pancreatic neuroendocrine tumours (PanNETs) are considered a relatively unusual oncologic entity. Due to its relative good prognosis, surgery remains the goal standard therapy not only in localized disease but also in the setting of locally or metastatic disease. Most of the patients are diagnosed in metastatic scenario, where multidisciplinary approach based on surgery, chemotherapies, liver-directed and/or molecular targeted therapies are commonly used. Owing to a deeper molecular knowledge of this disease, these targeted therapies are nowadays widely implemented, being the likely discovery of predictive biomarkers that would allow its use in other settings. This review is focused on describing the different classifications, etiology, prognostic biomarkers and multidisciplinary approaches that are typically used in PanNET.
胰腺神经内分泌肿瘤（PanNETs）被认为是一种相对罕见的肿瘤实体。由于其相对较好的预后，手术仍然是治疗的标准方案，不仅适用于局限性疾病，也适用于局部或转移性疾病。大多数患者在转移性疾病中被诊断出来，此时通常采用基于手术、化疗、肝定向和/或分子靶向治疗的多学科方法。由于对这种疾病有了更深入的分子认识，这些靶向治疗现在得到了广泛的应用，而预测生物标志物的发现可能使其在其他情况下得到应用。本综述重点描述了 PanNET 中常用的不同分类、病因、预后生物标志物和多学科方法。
